Neal
Nathanson Lectureship:
Nobel Laureate Dr. Prusiner
Dr. Prusiner's
Background
Stanley
B. Prusiner, M.D., is Director of the Institute for Neurodegenerative
Diseases and Professor of Neurology and Biochemistry at the University
of California, San Francisco. He received his undergraduate and
medical training at the University of Pennsylvania and his postgraduate
clinical training at UCSF. From 1969-72, he served in the U.S.
Public Health Service at the National Institutes of Health. Editor
of 8 books and author of over 250 research articles, Prusiner's
contributions to scientific research have been internationally
recognized. He is a member of the National Academy of Sciences,
the Institute of Medicine, the American Academy of Arts and Sciences,
the American Philosophical Society, and is a foreign member of
the Royal Society, London. He is the recipient of numerous prizes,
including the Potamkin Prize for Alzheimer's Disease Research
from the American Academy of Neurology (1991); the Richard Lounsbery
Award for Extraordinary Scientific Research in Biology and Medicine
from the National Academy of Sciences (1993); the Gairdner Foundation
International Award (1993); the Albert Lasker Award for Basic
Medical Research (1994); the Paul Ehrlich Prize from the Federal
Republic of Germany (1995); the Wolf Prize in Medicine from the
State of Israel (1996); the Keio International Award for Medical
Science (1996); the Louisa Gross Horwitz Prize from Columbia University
(1997); and the Nobel Prize in Physiology or Medicine (1997).
Dr.
Prusiner's Contributions
Stanley
Prusiner discovered an entirely new class of pathogens that replicate
without nucleic acid. Through this work, he created a new field
of research that has resulted in significant progress in understanding
degenerative diseases of the central nervous system (CNS). His
revolutionary studies have made conceptual advances in elucidating
mechanisms of age-dependent CNS diseases.
For several
decades, the prevailing concept was that the transmissible CNS
disease scrapie was caused by a slow-acting virus. Prusiner proposed
what many scientists considered to be the heretical idea that
the scrapie agent, which he called "prion," is composed
only of protein and is devoid of nucleic acid. His incisive experiments
demonstrated how an infectious pathogen lacking nucleic acid can
multiply and cause CNS degeneration.
After
purifying prions from the brain, he discovered that they are composed
of a single protein which he called "prion protein,"
or PrP. Prusiner found that a fragment of the protein polymerizes
into amyloid; next, he and his colleagues demonstrated that amyloid
plaques in the brains of animals and humans dying of prion diseases
are composed of PrP. This was the first time that cerebral amyloid
was shown to be the cause of a CNS disease.
Prusiner
and his colleagues discovered that disease causing scrapie PrP
was derived from normal cellular PrP which is encoded by a chromosomal
gene found in all animals examined. They determined that the tempo
of scrapie in animals is controlled by the sequence of PrP and
that the human diseases Gerstmann-Sträussler-Scheinker and
familial Creutzfeldt-Jakob are caused by mutations in the PrP
gene. This work identified the first mutations causing a CNS degenerative
disease. Transgenic mice harboring PrP genes with a human disease
mutation develop neurodegeneration spontaneously and transmit
disease to inoculated recipients. These studies revealed how a
disease can be both inherited and infectious, an unprecedented
concept in the study of disease pathogenesis.
Unable
to find a chemical difference that distinguished cellular PrP
from scrapie PrP, Prusiner and his colleagues demonstrated that
the two PrP forms have different conformations, or shapes. Scrapie
PrP is required initially for the change in shape to occur, thus,
scrapie PrP functions as both a ligand and the product of the
reaction. It also seems likely that a molecular chaperone mediates
the conversion. Prion diseases appear to be the first recognized
disorders of protein conformation.
The extraordinary
studies of Prusiner and his many very talented colleagues have
significantly changed the way scientists and physicians think
about CNS degenerative diseases. The unexpected results of their
studies may have profound implications for future biomedical research
in many areas of investigation.